Delivery Order SPE2DB22D3004-SPE2DB25FRS39
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $3,267.56 by the Defense Logistics Agency on August 13, 2025, for the supply of Prevnar 20 vaccine in 0.5mL syringes. The contract utilizes firm fixed price terms with an ultimate completion date of August 14, 2025, and was competitively awarded without set-aside designation. This delivery order is issued under AmerisourceBergen's existing Indefinite...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on July 22, 2025, for the supply of Prevnar 20 Syringe 0.5ML vaccines. This competitively awarded, firm fixed-price delivery order has a ceiling value of $73,941.30 and an ultimate completion date of July 23, 2025. The contract represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 4, 2025, for the supply of PREVNAR 20 vaccine in syringe form (0.5mL). This competitively awarded, firm fixed-price delivery order carries a ceiling value of $6,173.32 and is scheduled for completion by August 5, 2025. The place of performance is the contractor's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 8, 2025, for the supply of Prevnar 20 vaccine in 0.5mL syringes. The contract, valued at $98,026.20 with a firm fixed price structure, is scheduled for completion by August 11, 2025, and will be performed at the company's corporate office location in Conshohocken, PA 19428. This is a competitively awarded,...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $32,675.40 by the Defense Logistics Agency on August 15, 2025, for the supply of Prevnar 20 vaccine in 0.5 mL syringe format. This is a firm fixed-price contract with an ultimate completion date of August 18, 2025, with no set-aside designation applied. The award represents a competitively-bid delivery order executed under the company's existing contract vehicle with DLA, reflecting the agency's continued reliance on...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $1,633.77 by the Defense Logistics Agency (DLA) on July 28, 2025, for the supply of Prevnar 20 vaccine in 0.5mL syringes. The award is a firm fixed price, non-set-aside delivery order with an ultimate completion date of July 29, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $5,299.25 by the Defense Logistics Agency (DLA) on August 12, 2025, for the supply of PREVNAR 20 Syringe 0.5ML, a pneumococcal vaccine product. The contract is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will take place at the company's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of August 13, 2025. This award is...
- The Defense Logistics Agency awarded a $17,790.58 delivery order to AmerisourceBergen Drug Corp for PREVNAR 20 vaccine in 0.5ml syringes on August 15, 2025, with a completion date of August 18, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $27,844.80 to AmerisourceBergen Drug Corp for the supply of PREVNAR 20 vaccine in 0.5 mL syringes. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 6, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a child award under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for Prevnar 20 syringes (0.5mL) valued at $21.8K, with a completion date of August 11, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FRS39Delivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at approximately $31.8K by the Defense Logistics Agency (DLA) on July 30, 2025, with a completion date of July 31, 2025. The contract involves the supply of PREVNAR 20 vaccine in syringe form (0.5mL), utilizing firm fixed price terms with no set-aside designation. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which holds a one billion dollar ceiling value through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. The PREVNAR 20 delivery supports the Defense Health Agency and broader U.S. military healthcare systems' pharmaceutical supply requirements. AmerisourceBergen's federal procurement profile demonstrates extensive capability in fulfilling competitive medical supply needs across multiple therapeutic domains, with this award exemplifying the company's role as a critical vendor for federal vaccine and pharmaceutical distribution. The DLA's anticipated establishment of Pharmaceutical Prime Vendor Global Program Generation V contracts, designed to make multiple regional awards among different contractors, reflects the agency's strategic approach to ensuring robust pharmaceutical supply chain capacity across military and federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $31.8k | 7/30/25 |